Thus, HER2-low tumors represent a subgroup with potential therapeutic value, and precision medicine for this subgroup of tumors might benefit patients with breast cancer, especially those with triple-negative breast cancer (TNBC) for whom therapy strategies are scarce (11, 12). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.